Sort   by:  
 Page size 
GenomicsMesothelioma xenografts in nude mice: PBS treated versus pirfenidone treated
Mesothelioma xenografts in nude mice: PBS treated versus pirfenidone treated
PRJNA454010 | ENA
GenomicsEffect of pirfenidone on serum-stimulated human lung fibroblasts
Effect of pirfenidone on serum-stimulated human lung fibroblasts
PRJNA939233 | ENA
GenomicsEffect of Pirfenidone on NSCLC [A549 1.5 mg/ml Pirf 6hrs]
Effect of Pirfenidone on NSCLC [A549 1.5 mg/ml Pirf 6hrs]
PRJNA564082 | ENA
GenomicsEffect of Pirfenidone on NSCLC [A549/H1975 0.75 mg/ml Pirf]
Effect of Pirfenidone on NSCLC [A549/H1975 0.75 mg/ml Pirf]
PRJNA564081 | ENA
GenomicsEffect of Pirfenidone on NSCLC [A549 1.5 mg/ml Pirf 24hrs]
Effect of Pirfenidone on NSCLC [A549 1.5 mg/ml Pirf 24hrs]
PRJNA564085 | ENA
GenomicsRedundant effects of Pirfenidone against fibroblast activation and severe fibrotic lung disease
Redundant effects of Pirfenidone against fibroblast activation and severe fibrotic lung disease
PRJNA818159 | ENA
TranscriptomicsMesothelioma xenografts in nude mice: PBS treated versus pirfenidone treated
Background: Malignant mesothelioma is an aggressive cancer with poor prognosis. It is characterized by prominent extracellular matrix, mesenchymal tumor cell phenotypes and chemoresistance. In this study, the ability of pirfenidone to alter mesothelioma cell proliferation and migration as well as me...
ORGANISM(S): Homo sapiens 
2018-12-14 | GSE113803 | GEO
GenomicsNintedanib and Pirfenidone affect growth and differentiation of human alveolar type 2 cells
Nintedanib and Pirfenidone affect growth and differentiation of human alveolar type 2 cells
PRJNA1432010 | ENA
TranscriptomicsRedundant effects of Pirfenidone against fibroblast activation and severe fibrotic lung disease
Idiopathic Pulmonary Fibrosis (IPF) is a progressive chronic lung disease characterized by excess deposition of extracellular matrix (ECM) proteins in the lung. TGFα is a is a ligand for the epidermal growth factor receptor, and found elevated in several fibrotic lung diseases including IPF. Notably...
ORGANISM(S): Mus musculus 
2022-06-01 | GSE199034 | GEO
TranscriptomicsEffect of pirfenidone on serum-stimulated human lung fibroblasts
Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with a poor prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Pirfenidone was approved as an anti-fibrotic drug for IPF treatment as it is able to slow disease progression. The mechanisms by which the...
ORGANISM(S): Homo sapiens 
2023-05-12 | GSE226249 | GEO
Sort   by:  
 Page size